네이처셀

007390KOSDAQ기초 의약물질 제조업

41.5 / 100

Reference Date: 2026-04-13

Financial Score15.0 / 40

News Sentiment12.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Declined 6.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

NatureCell focuses on developing and selling stem cell therapies (e.g., JointStem, AstroStem), stem cell culture media, cosmetics, and beverage R&D and sales. The company is expanding its global presence through clinical trials in the U.S. and Japan, as well as a 2022 acquisition of a U.S. subsidiary. In 2024, the stem cell business accounted for approximately 68% of total revenue.

Number of Employees

83people

Average Salary

45.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 33.454.0Point

PBR

19.29Industry Average 2.030.0Point

9.5x industry avg (risky)

ROE

-4.45Industry Average -4.293.5Point

In line with industry avg

Debt Ratio

4.76Industry Average 6.615.0Point

Lower than industry avg (good)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲15.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼302.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -7.4% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 2Neutral 2Negative 0Average Sentiment Score 50

Neutral
日 줄기세포 치료 환자 사망사건, 보건·금융당국도 예의주시
일본 원정 줄기세포 치료 중 한국인 환자 사망 사건에 대해 보건·금융당국이 예의주시하고 있으며, 네이처셀 관계사 바이오스타줄기세포기술연구원도 언급되었습니다.
Positive
라정찬, 2년 만에 네이처셀 대표이사로 복귀
라정찬 네이처셀 회장이 2년 만에 대표이사로 복귀하여 줄기세포 사업 강화를 위한 책임경영 체제를 구축했습니다.
Positive
네이처셀, 라정찬 대표 체제로 변경…줄기세포사업 강화
네이처셀은 이사회 결의를 통해 라정찬 대표이사 체제로 변경하며 줄기세포 사업 강화를 위한 책임경영 체제를 구축한다고 밝혔습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (9%, downtrend)

Current 18,870Won52-week high 37,80052-week low 16,900

1-month return2.0Point

1m -6.81% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral정기주주총회결과2026-03-31
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-27
Neutral감사보고서제출2026-03-23
Neutral사업보고서 (2025.12)2026-03-23
Neutral대표이사변경2026-03-20